AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8072818
Drug: Bivalent pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent pneumococcal capsular polysaccharide (CPS)‐protein conjugate vaccines with serotypes 6A and 23F
Trial: 8072818
Drug: Bivalent pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent pneumococcal conjugate vaccine with native CPS directly linked to the carrier protein
Trial: 8072818
Drug: Bivalent pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent pneumococcal conjugate vaccines with smaller CPS or a six‐carbon linker
Trial: 8072818
Drug: Licensed pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed pneumococcal vaccine
Trial: 3186274
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg naloxone i.v.
Trial: 3186274
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg naloxone i.v.
Trial: 28686535
Drug: PET-CT normalization
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-CT normalization before maintenance therapy
Trial: 23782709
Drug: Individualized, meridian‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, meridian‐based syndrome differentiation and Sa‐am acupuncture treatment
Trial: 23782709
Drug: Standard acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard acupuncture treatment
Trial: 23782709
Drug: No acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No acupuncture treatment
Trial: 21895884
Drug: entacapone 200
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entacapone 200 mg with each levodopa dose
Trial: 19108956
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Alcohol (0.33 ml alcohol/kg body weight)
Trial: 19108956
Drug: Moderate Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Dose Alcohol (0.75 ml/kg)
Trial: 11763935
Drug: 0.03% triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% triclosan mouthrinse (15 ml, twice daily for 21 days)
Trial: 11763935
Drug: Placebo mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthrinse (15 ml, twice daily for 21 days)
Trial: 8225695
Drug: silybin 240
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silybin 240 mg b.i.d.
Trial: 3544654
Drug: Femoxetine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine 600 mg
Trial: 18695158
Drug: Carbidopa-levodopa 37.5/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa-levodopa 37.5/150 mg daily
Trial: 18695158
Drug: Carbidopa-levodopa 75/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa-levodopa 75/300 mg daily
Trial: 18695158
Drug: Carbidopa-levodopa 150/600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa-levodopa 150/600 mg daily
Trial: 9753211
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg/Kg intravenously
Trial: 9753211
Drug: Ondansetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.2 mg/Kg intravenously
Trial: 9753211
Drug: 0.07 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/Kg diazepam orally
Trial: 3110315
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g preoperative oral dose)
Trial: 3110315
Drug: Pivampicillin (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (high-dose short-term broad spectrum penicillin)
Trial: 31028900
Drug: Upper-limb robotic-assisted
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper-limb robotic-assisted therapy (RAT)
Trial: 24288364
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d) plus telmisartan (80 mg/d)
Trial: 24288364
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d) plus irbesartan (300 mg/d)
Trial: 24288364
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d) plus olmesartan (20 mg/d)
Trial: 21399485
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 to 10 mg/d) for 6 months
Trial: 18685810
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg every other day
Trial: 9181906
Drug: Nephrectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days)
Trial: 9181906
Drug: Nephrectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrectomy plus preoperative subcutaneous immunotherapy with IL-2
Trial: 31965842
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052)
Trial: 21716146
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m on days 1 and 8 every 21 days (Arm A)
Trial: 21716146
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily (Arm B)
Trial: 21716146
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m on days 1 and 8 every 21 days and erlotinib 100 mg daily (Arm C)
Trial: 17313002
Drug: Electroacupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture at Hegu (LI 4) and intravenous drip of oxytocin
Trial: 17313002
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of oxytocin
Trial: 1585959
Drug: Nonspecific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific treatment
Trial: 3898891
Drug: Placebo bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bupivacaine injection
Trial: 30458732
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition, followed on progression by fulvestrant
Trial: 30458732
Drug: First-line treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line treatment with a non-steroidal aromatase inhibitor, followed on progression by fulvestrant combined with CDK4/6 inhibition
Trial: 25277144
Drug: Selexipag (400-1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (400-1,800 µg, twice daily for 3 days)
Trial: 22402145
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to 7.5 mg/day in 7 weeks
Trial: 17297026
Drug: Primaquine 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 210 mg
Trial: 17297026
Drug: Primaquine 315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 315 mg
Trial: 17297026
Drug: Primaquine 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 420 mg
Trial: 17297026
Drug: Weight-based primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based primaquine dose
Trial: 9158465
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection alone
Trial: 9158465
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection plus heat probe treatment
Trial: 9158465
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection alone (subgroup with spurting haemorrhage)
Trial: 9158465
Drug: Adrenaline injection
RxNorm normalized name: epinephrine Injection [Adrenalin]
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenaline injection plus heat probe treatment (subgroup with spurting haemorrhage)
Trial: 8260854
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (fluticasone propionate [FP] 100 micrograms twice daily)
Trial: 27690510
Drug: Solution hints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution hints available
Trial: 27690510
Drug: No solution
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No solution hints available
Trial: 16781588
Drug: EPs 7630
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs 7630 (30 drops three times daily for seven days)
Trial: 16781588
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 drops three times daily for seven days)
Trial: 6106612
Drug: Halazepam 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halazepam 120 mg
Trial: 6106612
Drug: Halazepam 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halazepam 60 mg
Trial: 16968580
Drug: Omalizumab add-on
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab add-on therapy
Trial: 21434337
Drug: Nuanxin Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuanxin Capsule (NXC)
Trial: 19376452
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (1500 mg per day)
Trial: 19839182
Drug: Pravastatin-acetylsalicylic acid
RxNorm normalized name: pravastatin and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin-acetylsalicylic acid combination
Trial: 11920767
Drug: 17-beta-estradiol matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-beta-estradiol matrix patch (first patch worn for 4 days, second for 3 days, third for 4 days)
Trial: 11920767
Drug: 17-beta-estradiol matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-beta-estradiol matrix patch (control group without E(2) pretreatment)
Trial: 8004359
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) alone
Trial: 8004359
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) with Sho‐saiko‐to (TJ‐9)
Trial: 8004359
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) with Rikkunshi‐to (TJ‐43)
Trial: 8004359
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) with Sairei‐to (TJ‐114)
Trial: 2620951
Drug: Intramuscular iron-dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron-dextran complex
Trial: 2620951
Drug: Intravenous iron-dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron-dextran complex
Trial: 22882007
Drug: Subconjunctival 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of surgery (Group 2)
Trial: 18194593
Drug: Low-dose medical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose medical food emulsion (0.75 g GLA + 0.5 g EPA)
Trial: 18194593
Drug: High-dose medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medical food emulsion (1.13 g GLA + 0.75 g EPA)
Trial: 18194593
Drug: Low-dose medical
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose medical food emulsion (EFF1009)
Trial: 16407665
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone (1 approximately 3 mg/kg/day for 3 days)
Trial: 16407665
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intravenous prednisolone)
Trial: 8912147
Drug: Torasemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (40 mg)
Trial: 6337700
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG (120 mg in 50 ml saline) administered weekly for 6 weeks
Trial: 31787586
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 4 g/d
Trial: 26499756
Drug: Whey isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey isolate protein drink (12.5 g)
Trial: 26499756
Drug: Whey isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey isolate protein drink (50 g)
Trial: 26499756
Drug: Whey isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey isolate protein drink (75 g)
Trial: 26499756
Drug: Whey isolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey isolate protein drink (100 g)
Trial: 26499756
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (20 g)
Trial: 24374803
Drug: Glutamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 0.5 g/kg
Trial: 24374803
Drug: 18AA‐II solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18AA‐II solution
Trial: 16685547
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1,000 mg day(-1))
Trial: 10781923
Drug: Ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.3 mg/kg, Ketalar)
Trial: 8834420
Drug: Buprenorphine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (average dose = 9.0 mg/day sublingually)
Trial: 8834420
Drug: Methadone (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (average dose = 54 mg/day orally)
Trial: 1432467
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg/kg body weight/day) for 2 weeks
Trial: 1432467
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in multivitamin syrup for 2 weeks
Trial: 28135389
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone intervention problem solving (TIPS)
Trial: 23966217
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid (S)
Trial: 19126319
Drug: Dilapan-S™ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilapan-S™ and misoprostol combination
Trial: 17606053
Drug: 1 injection
RxNorm normalized name: vitamin K1 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of injectable mixed subtype collagenase
Trial: 17606053
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of injectable mixed subtype collagenase
Trial: 17606053
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with injectable mixed subtype collagenase
Trial: 15478484
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium fluoride (NaF) bioerodible gel
Trial: 15478484
Drug: Control gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control gel (no treatment)
Trial: 8018000
Drug: Aspirin (combined)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (combined)
Trial: 29025837
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 at a dose of 10^9 colony-forming units, orally, once daily for 6 months.
Trial: 29025837
Drug: Placebo, identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, identically appearing, orally, once daily for 6 months.
Trial: 22164492
Drug: Capsule Xinganbao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Xinganbao
Trial: 12713211
Drug: After-school intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After-school intervention focused on increasing physical activity and healthy eating, conducted twice a week for 12 weeks
Trial: 11095423
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg PEG‐OB weekly subcutaneous injections
Trial: 1319187
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg/kg with thiopental sodium, fentanyl, and midazolam, maintained with 70% nitrous oxide in oxygen
Trial: 2934708
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (4-6 mg/mg/day) introduced at 3rd month after transplantation
Trial: 2934708
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (prednisone, azathioprine, and antilymphocyte serum)
Trial: 23059149
Drug: Wake therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wake therapy with bright light therapy and sleep time stabilization
Trial: 18420531
Drug: Pegloticase 12
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase 12 mg every 4 weeks
Trial: 18420531
Drug: Pegloticase 4
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase 4 mg every 2 weeks
Trial: 18759308
Drug: Infusion-day adverse
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion-day adverse events
Trial: 18759308
Drug: Antipegloticase antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipegloticase antibody presence
Trial: 12136446
Drug: Manualized Psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized Psychodynamic Therapy
Trial: 7486839
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg added caffeine
Trial: 31215092
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (escalating daily doses from 400 to 4800 IU)
Trial: 18344024
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (three cycles of 3-weekly FEC(100) then three cycles of 3-weekly Doc 100 mg/m(2))
Trial: 18344024
Drug: Dose-dense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense treatment (four 10- to 11-day cycles of FEC(75) then four 2-weekly cycles of Doc 75 mg/m(2))
Trial: 18344024
Drug: Dose-dense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense treatment (Doc given after FEC)
Trial: 23948349
Drug: Dose-dense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense treatment
Trial: 16978370
Drug: RSGMET (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSGMET (4 mg rosiglitazone / 500 mg metformin, escalated to 8 mg/2 g)
Trial: 16978370
Drug: MET (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET (500 mg, escalated to 3 g)
Trial: 15325604
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with anal fissure before treatment
Trial: 11843992
Drug: Ciprofloxacin (CIP)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP) oral suspension (250 mg/5 mL twice daily)
Trial: 11843992
Drug: Trimethoprim/sulfamethoxazole (TMP/SMX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension (160/800 mg/20 mL twice daily)
Trial: 9763553
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous Ig (IVIg) (1 g/kg/d for 2 days)
Trial: 9763553
Drug: Long-term IVIg
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term IVIg therapy (repeated single infusions every 21 days)